Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,196 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05354674 | Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis | not yet recruiting | — | 302 | Fudan UniversityOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT05443841 | Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)(ECTOP-2005) | recruiting | — | 385 | Fudan UniversityOTHER | 1 |
| Jul 13, 2023 |
| clinicaltrials |
| NCT01833572 | Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001) | completed | Phase 2 | 36 | Fudan UniversityOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT05942378 | A Study of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | Fudan UniversityOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT05940441 | A Prospective Exploratory Clinical Study of Metronomic Capecitabine as Adjuvant Therapy in Locoregionally Advanced Hypopharyngeal Carcinoma | recruiting | — | 74 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05928780 | An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2) | unknown | Phase 1 / Phase 2 | 125 | Fudan UniversityOTHER | 0 | Jul 3, 2023 | clinicaltrials |
| NCT05823987 | Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05)(OPTIONS-05) | unknown | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT05824325 | Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer(GALAXY) | active not recruiting | Phase 1 / Phase 2 | 56 | Fudan UniversityOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT05883852 | EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer | recruiting | Phase 3 | 1,406 | Fudan UniversityOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT05893056 | Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Gastric Cancer Liver Metastasis (CASTLE-09)(CASTLE-09) | unknown | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT05897268 | Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)(CASTLE-10) | unknown | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT05921617 | A Cohort Study of Musculoskeletal Health in Patients With Breast Cancer During Aromatase Inhibitors Therapy | unknown | — | 870 | Fudan UniversityOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT05907512 | Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma | unknown | Phase 2 | 43 | Fudan UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05914402 | Axillary Surgery De-escalation After Neoadjuvant Therapy Using Dedicate Breast PET(NeoaPET) | unknown | N/A | 100 | Fudan UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05910034 | Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC | unknown | Phase 2 | 132 | Fudan UniversityOTHER | 0 | Jun 18, 2023 | clinicaltrials |
| NCT05892380 | The Clinical Value of an Artificial Intelligence System Using Abbreviated Protocol of Breast MRI Facilitates Classification of Breast Lessions | unknown | — | 800 | Fudan UniversityOTHER | 1 | Jun 7, 2023 | clinicaltrials |
| NCT05889871 | A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer | unknown | Phase 3 | 916 | Fudan UniversityOTHER | 0 | Jun 5, 2023 | clinicaltrials |
| NCT04265937 | ScreenIng of Genetic Susceptibility Genes for Breast Cancer Patients in CHinese communiTies(SIGHT) | unknown | — | 5,000 | Fudan UniversityOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05881746 | Anatomical Resection VS. Nonanatomical Resection for Colorectal Liver Metastases With Gene Mutation or Right-sidedness | not yet recruiting | N/A | 176 | Fudan UniversityOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05873972 | Multimodal Model for Efficacy Prediction Cetuximab in Colorectal Cancer Liver Metastasis Patient | unknown | N/A | 100 | Fudan UniversityOTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT03737539 | Dynamic Monitoring of ctDNA Methylation to Predict Relapse in Colorectal Cancer After Radical Resection (POSTCA) | unknown | — | 300 | Fudan UniversityOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT05771025 | Effect of Hepatectomy on the Prognosis of Patients With Nasopharyngeal Carcinoma Liver Metastases | unknown | N/A | 55 | Fudan UniversityOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT05853094 | Postoperative Effects of Different Enterostomy Approaches | recruiting | N/A | 300 | Fudan UniversityOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT05863260 | Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical Cancer | unknown | — | 60 | Fudan UniversityOTHER | 1 | May 18, 2023 | clinicaltrials |
| NCT04855331 | Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPC | unknown | N/A | 120 | Fudan UniversityOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT05688488 | Clinical Study of Curcumin in Preventing Postoperative Adhesion of Bilateral Vocal Cords | recruiting | Phase 1 / Phase 2 | 100 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05839002 | Primary Tumor Burden Score:A Novel Staging Parameter for ESCC After nCRT | completed | — | 187 | Fudan UniversityOTHER | 0 | May 3, 2023 | clinicaltrials |
| NCT05839288 | Pyrotinib Plus Trastuzumab and Chemotherapy in HER2+ Metastatic Breast Cancer Patients | completed | — | 161 | Fudan UniversityOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT05841381 | Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer | not yet recruiting | Phase 3 | 876 | Fudan UniversityOTHER | 0 | May 3, 2023 | clinicaltrials |
| NCT05819060 | The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab | unknown | Phase 2 | 44 | Fudan UniversityOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT05806047 | Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy | unknown | Phase 2 | 23 | Fudan UniversityOTHER | 0 | Apr 10, 2023 | clinicaltrials |
| NCT05594082 | Real-world Effectiveness and Safety Study of T-Dxd in Chinese Metastatic Breast Cancer | unknown | — | 150 | Fudan UniversityOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05781074 | Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer (CASTLE-08)(CASTLE-08) | unknown | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05772208 | Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy | recruiting | Phase 3 | 459 | Fudan UniversityOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT05759312 | Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma | unknown | Phase 1 / Phase 2 | 20 | Fudan UniversityOTHER | 0 | Mar 8, 2023 | clinicaltrials |
| NCT03772353 | Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer(PLEASURABLE) | unknown | Phase 1 / Phase 2 | 59 | Fudan UniversityOTHER | 1 | Mar 7, 2023 | clinicaltrials |
| NCT05675462 | Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 | 25 | Fudan UniversityOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT05670925 | A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC. | unknown | Phase 2 | 46 | Fudan UniversityOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT05744518 | Monitoring Response to Neoadjuvant Chemotherapy in Breast Cancer Using Ultrafast DCE-MRI | unknown | — | 80 | Fudan UniversityOTHER | 1 | Feb 27, 2023 | clinicaltrials |
| NCT05732129 | The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer. | unknown | Phase 2 | 29 | Fudan UniversityOTHER | 1 | Feb 24, 2023 | clinicaltrials |
| NCT05732493 | Short-course Radiotherapy Combined With Chemotherapy and Pd-1 Inhibitor for Locally Advanced Colon Cancer(TORCH-C)(TORCH-C) | unknown | Phase 2 | 120 | Fudan UniversityOTHER | 0 | Feb 17, 2023 | clinicaltrials |
| NCT05386524 | Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC | unknown | Phase 2 | 41 | Fudan UniversityOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT05721300 | Study on Screening, Verification and Intervention of High-risk Patients With Liver Cancer | unknown | N/A | 2,215 | Zhongshan Hospital (Xiamen), Fudan UniversityOTHER | 1 | Feb 10, 2023 | clinicaltrials |
| NCT03374566 | Immunodeficiency for Severe Epstein-Barr Virus Infection | completed | — | 100 | Children's Hospital of Fudan UniversityOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT05717582 | Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment(CHAMPION) | not yet recruiting | Phase 2 | 47 | Fudan UniversityOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT04077515 | Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma | completed | Phase 4 | 92 | Children's Hospital of Fudan UniversityOTHER | 1 | Jan 30, 2023 | clinicaltrials |
| NCT04984980 | Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer | unknown | Phase 2 | 37 | Fudan UniversityOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05697926 | Preclinical Research for Personalized TCR-T Therapy for Head and Neck Cancer | unknown | — | 100 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT04582968 | Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases | unknown | Phase 1 / Phase 2 | 39 | Fudan UniversityOTHER | 1 | Jan 18, 2023 | clinicaltrials |
| NCT05688033 | Dosimetric Limitation of Pelvic Bone and Peritoneal Space in Rectal Cancer Patients During Chemoradiotherapy | unknown | N/A | 200 | Fudan UniversityOTHER | 1 | Jan 18, 2023 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials